NFL BIOSCIENCES: Determination to approve the issuing of its patent in South Korea
NFL BIOSCIENCES (Euronext Development Paris – FR0014003XT0 – ALNFL), a biopharmaceutical firm creating botanical medicine for the therapy of addictions, is asserting that it has obtained approval from the South Korean mental property workplace for issuing its patent (South Korean utility no.10-2018-7032224) for NFL-101, a nicotine-free botanical drug candidate comprising pure proteins extracted from tobacco leaves, targeted totally on smoking cessation. This patent will shield the innovation that NFL-101 is predicated on by way of to 2036 in South Korea.
NFL Biosciences has adopted a information administration and safety technique that led it to submit two patent households granting it unique rights to its drug candidate NFL-101. This product patent, initially registered and accredited in France, issues an “aqueous extract of tobacco leaves and its use for the therapy of dependence”. The innovation that NFL-101 is predicated on is subsequently protected by way of to 2036 in France, the US, China and now South Korea. Nationwide registration purposes are additionally within the evaluation part within the following areas and international locations: Japan, Canada, Australia, Brazil, India, Indonesia, Israel, Mexico, Philippines, Eurasia, Saudi Arabia, United Arab Emirates and Nigeria.
South Korea has greater than 9 million every day people who smoke1.
“We’re persevering with to maneuver ahead with our patent registration schedule in step with our international technique. Following China, the securing of this patent in South Korea will additional strengthen the safety of the innovation behind NFL-101. We’re persevering with to construct our protection throughout Asia, a key area within the struggle in opposition to smoking and a significant marketplace for NFL Biosciences and its drug candidate”, confirms Bruno Lafont, Chief Working Officer and co-founder of NFL Biosciences.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical firm primarily based within the Montpellier space which develops botanical drug candidates for the therapy of addictions. NFL Biosciences’ ambition is to deliver new, pure, safer and simpler therapeutic options to the whole world inhabitants, together with low- and middle-income international locations. Its most superior product, referred to as NFL-101, is a standardized, nicotine-free tobacco leaf extract protected by two patent households. NFL Biosciences intends to supply people who smoke who wish to stop a pure, protected, easy-to-administer and personalised different. NFL Biosciences can also be creating NFL-301, a pure drug candidate for the discount of alcohol consumption and has a drug improvement undertaking for the therapy of hashish use issues.
The shares of NFL Biosciences are listed on Euronext Development Paris (FR0014003XT0 – ALNFL). Discover out extra at www.nflbiosciences.com
Contacts
Bruno Lafont – information@nflbiosciences.com – 04 11 93 76 67 Agence Calyptus – nflbio@calyptus.internet – 01 53 65 68 68
1 Supply: OECD.org (2019)
-
20220511_NFLBioscience_issuing_patent_South_Korea_EN_vDEF
© OMX, supply GlobeNewswire – EU Press Releases
